Look through the key statistics analysis before diving in deeper into our report:
Parameter | Current result | Assessment |
---|---|---|
Meta title | Avastin® (bevacizumab) Healthcare Professional Website | As meta title is a ranking factor, it's quite important to stick to search engine recommended length of aroun 50-60 characters. This website's meta title is 54 characters long. |
Description | Learn about Avastin® (bevacizumab) for FDA approved indications. Avastin is indicated for the treatment of glioblastoma as a single agent for adult patients with progressive disease following prior therapy. The effectiveness of Avastin in glioblastoma is based on an improvement in objective response rate. There are no data demonstrating an improvement in disease‐related symptoms or increased survival with Avastin. Avastin is indicated for the first‐ or second‐line treatment of patients with metastatic carcinoma of the colon or rectum in combination with intravenous 5‐fluorouracil–based chemotherapy. Avastin, in combination with fluoropyrimidine‐irinotecan‐ or fluoropyrimidine‐oxaliplatinbased chemotherapy, is indicated for the second‐line treatment of patients with metastatic colorectal cancer who have progressed on a first‐line Avastin‐containing regimen. Limitation of Use: Avastin is not indicated for adjuvant treatment of colon cancer. Avastin is indicated for the first‐line treatment of unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell lung cancer in combination with carboplatin and paclitaxel. Avastin is indicated for the treatment of metastatic renal cell carcinoma in combination with interferon alfa. Avastin in combination with paclitaxel and cisplatin or paclitaxel and topotecan is indicated for the treatment of persistent, recurrent, or metastatic carcinoma of the cervix. Avastin in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan is indicated for the treatment of patients with platinum‐resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. BOXED WARNINGS: Gastrointestinal (GI) perforation: Serious and sometimes fatal GI perforation occurs at a higher incidence in Avastin‐treated patients compared to controls. The incidences of GI perforation ranged from 0.3% to 3.2% across clinical studies. Discontinue Avastin in patients with GI perforation. Surgery and wound healing complications: The incidence of wound healing and surgical complications, including serious and fatal complications, is increased in Avastin‐treated patients. Do not initiate Avastin for at least 28 days after surgery and until the surgical wound is fully healed. The appropriate interval between termination of Avastin and subsequent elective surgery required to reduce the risks of impaired wound healing/wound dehiscence has not been determined. Discontinue Avastin at least 28 days prior to elective surgery and in patients with wound healing complications requiring medical intervention. Hemorrhage: Severe or fatal hemorrhage, including hemoptysis, GI bleeding, hematemesis, central nervous system hemorrhage, epistaxis, and vaginal bleeding, occurred up to 5‐fold more frequently in patients receiving Avastin. Across indications, the incidence of grade ≥3 hemorrhagic events among patients receiving Avastin ranged from 0.4% to 6.9%. Do not administer Avastin to patients with serious hemorrhage or recent hemoptysis (≥1/2 tsp of red blood). Discontinue Avastin in patients with serious hemorrhage (ie, requiring medical intervention). ADDITIONAL SERIOUS ADVERSE EVENTS: Additional serious and sometimes fatal adverse events with increased incidence in the Avastin‐treated arm vs control included: GI fistulae (up to 2% in metastatic colorectal cancer and ovarian cancer patients). Non‐GI fistulae (<1% in trials across various indications; 1.8% in a cervical cancer trial). Arterial thromboembolic events (grade ≥3, 2.6%). Proteinuria (nephrotic syndrome, <1%). Additional serious adverse events with increased incidence in the Avastin‐treated arm vs control included: GI‐vaginal fistulae occurred in 8.3% of patients in a cervical cancer trial. Venous thromboembolism (grade 3–4, up to 10.6%) in patients with persistent, recurrent, or metastatic cervical cancer treated with Avastin. Hypertension (grade 3–4, 5%–18%). Posterior reversible encephalopathy syndrome (PRES) (<0.5%). Infusion reactions with the first dose of Avastin were uncommon (<3%), and severe reactions occurred in 0.2% of patients. Inform females of reproductive potential of the risk of ovarian failure prior to starting treatment with Avastin. Avoid use in patients with ovarian cancer who have evidence of recto‐sigmoid involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction. PREGNANCY WARNING: Based on the mechanism of action and animal studies, Avastin may cause fetal harm. Advise female patients that Avastin may cause fetal harm, and to inform their healthcare provider of a known or suspected pregnancy. Advise females of reproductive potential to use effective contraception during treatment with Avastin and for 6 months after the last dose of Avastin. Advise nursing women that breastfeeding is not recommended during treatment with Avastin. Avastin may impair fertility. MOST COMMON ADVERSE EVENTS: Across indications, the most common adverse reactions observed in Avastin patients at a rate >10% and at least twice the control arm rate were: epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis. Across all studies, Avastin was discontinued in 8.4% to 21% of patients because of adverse reactions. You may report side effects to the FDA at (800) FDA‐1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835‐2555. Please see accompanying full Prescribing Information, including BOXED WARNINGS, for additional important safety information. | This meta description is 5681 characters in length. Google suggests up to 320 characters at the very most to make sure the whole meta description is visible in search results page. |
Site speed | Around 3.0126 seconds | Website ranking and usability can be greatly improved by reducing the time it takes to load it. |
Alexa global rank | 1661294, as last checked | Based on Alexa Global, we can assume the website is not very popular. Mind you, Alexa's worth is questionable at best. |
Quantcast | Current rank, according to our database, is at 528338 | Quantcast does not rank this website very high, which should in theory mean it's not that popular. Having said that, popularity is context-dependant, so take this with a grain of salt. |
Links on homepage | Around 145 links | This is a well-judged amount of links for a homepage. |
Backlinks amount | Approximately 9 | The number of backlinks seems awfully low. If possible, the webmaster should work towards building more through quality content and public awareness. |
HTML size | 151.7KB | Ah. Well. We were hoping for better results... We would urge the website owners to improve load speed as soon as possible. |
Website host server overview | Server status: online. Server IP address for this website is 52.52.237.169. | We apologize, but for some reason we were unable to gather enough data to provide a detailed insight at this time. |
If the basic information we presented you with above is not enough, get ready to dive in much deeper!
Now that the numbers are taken care of, we can go deeper and try to analyse the website from a user's perspective. More specifically, let's see if we can identify the target audience as well as a few related websites and categories.
Parameter | Current result | Assessment |
---|---|---|
Alternative websites | avastin.com cancerinfo.co.nz gffcc.org oncology.tv cyramzahcp.com |
These websites fall into the same categories as avastin-hcp.com, more or less. By extension, they compete with the analysed website for the same target audience. |
Trying to acquire very accurate visitor data is immensely difficult and can only be done when given direct access to the server. However, there are ways to get approximate numbers.
The numbers themselves probably say enough, but we'll add some insight where possible.
Parameter | Current result | Assessment |
---|---|---|
Approximate time on site | 1:58 | Pretty good for an average time spent, wouldn't you say? |
ALEXA rating is based on the number of visitors a given page receives. The higher the visitor count, the higher the rating. Currently, ALEXA has over 4 million websites indexed. If you sense cynicism in our words, you're not mistaken - we think Alexa rating is overrated, to put it mildly. A website's worth (and contextual popularity) is more than the sum of the views. So take the rank with a grain of salt.
QUANTCAST is a data processing company that mostly gathers information for advertising companies. It specializes in real-time audience analysis and, as you may have gathered, is really quite similar to Alexa, if perhaps not as infamous. To our knowledge, the company has rated and ranked approximately 518546016 websites so far. There is always a caveat with these sort of ranking systems - they don't really take any context into account. As such, their usefulness is debatable at best. Don't overthink this rank - it's just a number, really.
Servers are physical storage devices that contain all the files and databases associated with a specific website, sometimes more than one. At times, a server makes up several virtual devices - separate servers used for shared hosting (tends to be cheaper). Entering website address into the address bar of your browser starts the request process during which your browser contacts the server and asks for specific files and database entries in order to display the requested website.
What follows is certainly very geeky, but informative for the knowing. Dig in:
Header detail |
---|
HTTP/1.1 200 OK Accept-Ranges: bytes Content-Type: text/html; charset=UTF-8 Date: Sun, 29 Oct 2017 09:40:27 GMT ETag: "25c0d-55c8e96a61517" Last-Modified: Fri, 27 Oct 2017 22:12:46 GMT Server: Apache ServerID: web02 Content-Length: 154637 Connection: Close |
WHOIS |
---|
Whois Server Version 2.0 Domain names in the .com and .net domains can now be registered with many different competing registrars. Go to http://www.internic.net for detailed information. Domain Name: AVASTIN-HCP.COM Registrar: SAFENAMES LTD Sponsoring Registrar IANA ID: 447 Whois Server: whois.safenames.net Referral URL: http://www.safenames.net Name Server: DNADNS2E.GENE.COM Name Server: DNADNS3E.GENE.COM Name Server: DNADNS4E.GENE.COM Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Updated Date: 19-oct-2016 Creation Date: 25-oct-2012 Expiration Date: 25-oct-2017 >>> Last update of whois database: Thu, 30 Mar 2017 12:48:07 GMT <<< For more information on Whois status codes, please visit https://icann.org/epp NOTICE: The expiration date displayed in this record is the date the registrar's sponsorship of the domain name registration in the registry is currently set to expire. This date does not necessarily reflect the expiration date of the domain name registrant's agreement with the sponsoring registrar. Users may consult the sponsoring registrar's Whois database to view the registrar's reported date of expiration for this registration. TERMS OF USE: You are not authorized to access or query our Whois database through the use of electronic processes that are high-volume and automated except as reasonably necessary to register domain names or modify existing registrations; the Data in VeriSign Global Registry Services' ("VeriSign") Whois database is provided by VeriSign for information purposes only, and to assist persons in obtaining information about or related to a domain name registration record. VeriSign does not guarantee its accuracy. By submitting a Whois query, you agree to abide by the following terms of use: You agree that you may use this Data only for lawful purposes and that under no circumstances will you use this Data to: (1) allow, enable, or otherwise support the transmission of mass unsolicited, commercial advertising or solicitations via e-mail, telephone, or facsimile; or (2) enable high volume, automated, electronic processes that apply to VeriSign (or its computer systems). The compilation, repackaging, dissemination or other use of this Data is expressly prohibited without the prior written consent of VeriSign. You agree not to use electronic processes that are automated and high-volume to access or query the Whois database except as reasonably necessary to register domain names or modify existing registrations. VeriSign reserves the right to restrict your access to the Whois database in its sole discretion to ensure operational stability. VeriSign may restrict or terminate your access to the Whois database for failure to abide by these terms of use. VeriSign reserves the right to modify these terms at any time. The Registry database contains ONLY .COM, .NET, .EDU domains and Registrars. Domain Name: AVASTIN-HCP.COM Registry Domain ID: 1754738748_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.safenames.net Registrar URL: http://www.safenames.net Updated Date: 2016-10-19T06:12:52Z Creation Date: 2012-10-25T17:33:49Z Registrar Registration Expiration Date: 2017-10-25T17:33:49Z Registrar: Safenames Ltd Registrar IANA ID: 447 Registrar Abuse Contact Email: Registrar Abuse Contact Phone: +44.1908200022 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Registry Registrant ID: Not Available From Registry Registrant Name: Linda Daignault Registrant Organisation: Genentech, Inc Registrant Street: 1 DNA Way Registrant Street: Registrant City: South San Francisco Registrant State/Province: CA Registrant Postal Code: 94080 Registrant Country: US Registrant Phone: +1.6502257923 Registrant Fax: Registrant Email: Global. Registry Admin ID: Not Available From Registry Admin Name: global. Admin Organisation: F. Hoffmann-La Roche AG Admin Street: Grenzacherstrasse 124 Admin Street: Admin City: Basel Admin State/Province: Basel Admin Postal Code: 4070 Admin Country: CH Admin Phone: +41.55578787 Admin Fax: Admin Email: global. Registry Tech ID: Not Available From Registry Tech Name: International Domain Tech Tech Organisation: International Domain Tech Tech Street: Safenames House, Sunrise Parkway Tech Street: Tech City: Milton Keynes Tech State/Province: Bucks Tech Postal Code: MK14 6LS Tech Country: UK Tech Phone: +44.1908200022 Tech Fax: +44.1908325192 Tech Email: Name Server: DNADNS2E.GENE.COM Name Server: DNADNS3E.GENE.COM Name Server: DNADNS4E.GENE.COM DNSSEC: unsigned URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/ >>> Last update of WHOIS database: 2016-10-19T06:12:52Z <<< "For more information on Whois status codes, please visit https://icann.org/epp" Safenames - Experts in Global Domain Management and Online Brand Protection Domain Registration in over 760 different extensions Enterprise Domain Management since 1999 Mark Protect™ Online Brand Monitoring and Enforcement Domain Consulting and Strategy Domain Name Acquisition Domain Disputes and Recovery Visit Safenames at www.safenames.net +1 703 574 5313 in the US/Canada +44 1908 200022 in Europe The Data in the Safenames Registrar WHOIS database is provided by Safenames for information purposes only, and to assist persons in obtaining information about or related to a domain name registration record. Safenames does not guarantee its accuracy. Additionally, the data may not reflect updates to billing contact information. By submitting a WHOIS query, you agree to use this Data only for lawful purposes and that under no circumstances will you use this Data to: (1) allow, enable, or otherwise support the transmission of mass unsolicited, commercial advertising or solicitations via e-mail, telephone, or facsimile; or (2) enable high volume, automated, electronic processes that apply to Safenames (or its computer systems). The compilation, repackaging, dissemination or other use of this Data is expressly prohibited without the prior written consent of Safenames. Safenames reserves the right to terminate your access to the Safenames Registrar WHOIS database in its sole discretion, including without limitation, for excessive querying of the WHOIS database or for failure to otherwise abide by this policy. Safenames reserves the right to modify these terms at any time. By submitting this query, you agree to abide by this policy. |
Now that you are hopefully done with avastin-hcp.com, we invite you to read more of our in-depth reports. Try entering a new domain address in the search form at the top of this page, or on the homepage. Alternatively, refer to this list for more website overviews:
We have found so many alternative TLD extensions for avastin-hcp.com. Here is the full list with 580 entries:
The following list of most frequent domain address mistypes associated with avastin-hcp.com contains at least 1194 entries: